Cinética y capacidad neutralizante de los anticuerpos homólogos y ...

Referencias Bibliográficas
175. Kochel TJ, Watts DM, Halstead SB, Hayes CG, Espinoza A, Felices V, et al. Effect
of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic
fever. Lancet 2002;360(9329):310-2.
176. Halstead S. Dengue Virus-Mosquito Interactions. Annu Rev Entomol
2008;53:15.1-15.10.
177. Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: epidemiology,
pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr 1997;131(4):516-
24.
178. PAHO. Dengue and dengue hemorrhagic fever in the Americas: guidelines for
prevention and control.Scientific publication no.548. Washington: PAHO. 1994.
179. Monath TP. Dengue: the risk to developed and developing countries. Proc Natl
Acad Sci U S A 1994;91(7):2395-400.
180. Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever with
unusual manifestations. Southeast Asian J Trop Med Public Health 1987;18(3):398-406.
181. Gowrishankar K, Rajajee S. Varied manifestations of viral myocarditis. Indian J
Pediatr 1994;61(1):75-80.
182. Tolou H, Pisano MR, Deubel V, Nicoli J. Consequences of choice of the
immunization protein in the vaccines of the future against flavivirus. Travaux Scientifiques
Des Chercheurs Du Service De Sante Des Armees 1991;0(12):85-86.
183. Halstead SB. Vaccines aplenty. Curr Opin Infect Dis 2002;15(5):461-3.
184. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al.
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated
dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J
2004;23(2):99-109.
185. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine
2000;18 Suppl 2:44-7.
186. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al.
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult
volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg
2002;66(3):264-72.
187. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety
and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in
nonhuman primates. J Virol 2004;78(9):4761-75.
188. Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, et al. Synergistic
neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of
lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
Virology 2001;290(1):74-82.
189. Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, Mune M, et al.
Induction of neutralizing antibodies and partial protection from viral challenge in Macaca
fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed
in Pichia pastoris. Am J Trop Med Hyg 2003;69(2):129-34.
190. Hermida L, Rodriguez R, Lazo L, Bernardo L, Silva R, Zulueta A, et al. A fragment
of the envelope protein from dengue-1 virus, fused in two different sites of the
meningococcal P64k protein carrier, induces a functional immune response in mice.
Biotechnol Appl Biochem 2004;39(Pt 1):107-14.
131